Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Merrimack Pharma’s veteran chief goes in cost drive

Monday, October 3, 2016 6:26
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Merrimack Pharmaceuticals Inc  (NASDAQ:MACK) has unveiled a major retrenchment programme that will see its chief executive step down and almost a quarter of its workforce depart.

Robert Mulroy, chief executive for 17 years, will be replaced by chairman Gary Crocker on an interim basis until a permanent replacement is found.

Merrimack’s lead product in Onivyde, a US approved treatment for advanced pancreatic cancer sufferers, but it has a number of phase II trial results due next year and in 2018.

The cancer drug developer said today’s corporate overhaul would save US$200mln over the next two years and was part of a switch to biology-derived cancer products.

“This major restructuring will allow us to strategically align our pipeline with our core capabilities and prioritize ongoing clinical development efforts while improving our financial flexibility,” said Crocker.

Shares in Merrimack have dropped by almost a fifth this year so far.

Yasir Al-Wakeel, CFO and head of corporate development, added Merrimack was now in a much stronger financial position with a 12 months runway based on cash in hand, anticipated near term milestones and reimbursements and Onivyde profits.

Story by ProactiveInvestors

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.